Physician profile
Stephen George
NPI 1386628055
$19,973.34
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,094 · 2020: $2,930 · 2021: $3,081 · 2022: $3,146 · 2023: $4,388 · 2024: $2,334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,718 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,717.53 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,054.95 | 2019-2024 | Enbrel, Otezla, Prolia |
| Abbvie INC. | $2,180.61 | 2019-2024 | |
| Janssen Biotech, INC. | $1,744.08 | 2019-2024 | Simponi Aria, Tremfya |
| Novartis Pharmaceuticals Corporation | $1,546.88 | 2019-2024 | |
| Pfizer INC. | $1,415.93 | 2019-2024 | |
| Ucb, INC. | $1,156.43 | 2019-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $695.74 | 2019-2024 | Orencia |
| Horizon Therapeutics Plc | $639.31 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $624.65 | 2021-2024 | Saphnelo |
| Radius Health, INC. | $622.78 | 2019-2024 | Tymlos |
| Lilly USA, LLC | $622.02 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $618.73 | 2020-2024 | Acthar |
| Glaxosmithkline, LLC. | $522.51 | 2019-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $520.62 | 2022-2024 | Lupkynis |
| Genentech USA, INC. | $412.78 | 2019-2024 | Actemra, Rituxan |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.